Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging

Recruiting now · Phase 4

Conditions studied: Focal Liver Lesions

In brief

Liver tumours, 40% of which are benign, account for 1% to 4% of all solid tumours in children. The benign tumours are mainly haemangiomas, liver hamartomas, and liver cell adenomas. The malignant tumours are mainly hepatoblastoma, hepatocellular carcinoma (HCC), malignant liver mesothelioma, and rhabdomyosarcoma. The differential diagnosis of liver masses in children is generally based on the child's age, the clinical evaluation (including alpha-fetoprotein test results), and imaging characteristics. Liver tumours seldom produce clear symptoms and signs in the early stages, and they progress rapidly. As a result, most liver tumours are not diagnosed until the middle or late stages. To improve survival among patients with liver tumours, clinicians must find the liver tumours as early as possible and determine whether the tumours are benign or malignant. Conventional ultrasonography is commonly used for screening, and is preferred as the first-line imaging technique for children. Not only does it have a wide range of applications and a high diagnostic yield, but it is well accepted by patients and their parents. It can be performed in the examination room with the parents present, allowing real-time imaging and direct interaction with patient and parents. CEUS is a non-invasive imaging technology that can continuously and dynamically observe blood perfusion in tumours in real-time through injection of a contrast agent to enhance the blood flow reflux signal in the human body. Consequently, CEUS is useful for visualising capillaries and tissue perfusion in the human body. The purpose of this current study is to evaluate the use of Sonazoid™ perfluorobutane (PFB) microbubbles as a contrast medium for CEUS for evaluation of solitary liver masses in children.

Key facts

Study ID

NCT06639828

Run by

GE Healthcare

People needed

50

Starts

2025-01-20

Expected to finish

2026-10-31

Last updated by the study team

2026-03-04

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject is <18 years of age on the day of consent.
• The subject has at least 1 untreated FLL with ≤8 lesions (excluding cysts), with ≤8 cm confirmed in a diagnostic examination performed in the past month (or past 3 months if the lesion was benign) and that could also be visualised when obtained via unenhanced ultrasound imaging
• The subject has had a dynamic CECT or CEMRI examination within the past month or is scheduled to have one in the month following inclusion in the study, and these images are/would be available.
• The subject can comply with study procedures.
• Parents or legally authorised representatives have signed the Informed Consent Form approved for this study by the Independent Review Board (IRB)/Independent Ethics Committee (IEC). The form will indicate that the patient (and/or a legally acceptable representative) has been informed of all pertinent aspects of the study. Patients who are able to provide assent have signed an age-appropriate paediatric assent form
• Post-menarcheal female patients must have a negative urine pregnancy test at screening and at pre-dose on the dosing day.
• Post-menarcheal female patients and male patients who are sexually active with a partner of childbearing potential must be practicing abstinence or be using an effective form of birth control (See Section 8.6) for ≥30 days before being enrolled in the study
• The subject has a body weight of 3 kg or greater.
• The subject has a negative egg allergy test if the egg allergy status of the subject is unknown.

You may not qualify if…

• The subject has a known or suspected hypersensitivity to any of the components of Sonazoid™, including a history of allergies to eggs or egg products (i.e., manifested by full body rash, respiratory difficulty, oral or laryngeal swelling, hypotension, or shock).
• The subject has an acute clinically fatal condition (i.e., the expected survival is ≤6 months).
• The subject has previously received Sonazoid™ or another ultrasound contrast agent within the past 30 days.
• The subject had undergone or is planning to undergo an examination with a contrast agent (i.e., iodinated x-ray contrast agent, MRI contrast agent or another ultrasound contrast agent) within the 24 hours before or after Sonazoid™ injection.
• The subject has undergone or was undergoing systemic or loco-regional chemotherapy or radiation therapy
• The subject is participating in another clinical trial with an unregistered medicinal product, or less than 30 days has passed since the subject completed participation in such a trial
• The subject is a pregnant or lactating female.
• The physician judges that a large-enough needle (24-gauge or larger) cannot be inserted.
• The subject has a known right-left cardiac shunt.

Where it is running

• University Hospitals Bristol and Weston NHS Foundation Trust — Bristol, United Kingdom (enrolling)
• King's College Hospital NHS Foundation Trust — London, United Kingdom (enrolling)
• Imperial College Healthcare NHS Trust — London, United Kingdom (enrolling)
• Munich University Hospital — München, Germany
• Papa Giovanni XXIII Hospital — Bergamo, Italy
• Giannina Gaslini Institute — Genoa, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.